Per-protocol analysis set# | ITT analysis set# | |||||
Usual care | Urban Training | All | Usual care | Urban Training | All | |
Subjects n | 145 | 88 | 233 | 148 | 132 | 280 |
Age years | 69±8 | 69±9 | 69±8 | 69±8 | 68±9 | 69±8 |
Female/male | 17 (12)/128 (88) | 12 (14)/76 (86) | 29 (12)/204 (88) | 18 (12)/130 (88) | 18 (14)/114 (86) | 36 (13)/244 (87) |
Active smoker | 29 (20) | 20 (22) | 49 (21) | 30 (20) | 34 (26) | 64 (23) |
Low socioeconomic status¶ | 105 (73) | 64 (73) | 169 (73) | 107 (73) | 93 (71) | 200 (72) |
Active worker | 16 (12) | 13 (15) | 29 (13) | 16 (11) | 19 (15) | 35 (13) |
Dyspnoea mMRC grade (0–4) | 1±1 | 1±1 | 1±1 | 1±1 | 1±1 | 1±1 |
Post-bronchodilator FEV1 % pred | 58±18 | 57±16 | 58±17 | 58±18 | 56±17 | 57±17 |
Post-bronchodilator FEV1/FVC ratio | 0.55±0.12 | 0.54±0.10 | 0.54±0.12 | 0.55±0.12 | 0.53±0.11 | 0.54±0.12 |
Airflow limitation+ mild/moderate/severe/very severe % | 10/55/30/5 | 8/57/31/4 | 9/55/31/5 | 10/54/30/6 | 9/51/32/8 | 10/53/31/6 |
GOLD 2017 assessment+ (A/B/C/D) % | 37/44/7/12 | 35/52/0/13 | 36/47/4/13 | 36/44/7/13 | 31/53/3/13 | 34/48/5/13 |
Cardiovascular disease§ | 88 (61) | 52 (60) | 140 (60) | 90 (61) | 81 (62) | 171 (61) |
Diabetes mellitus§ | 37 (26) | 25 (29) | 62 (27) | 38 (26) | 44 (34) | 82 (29) |
Musculoskeletal diseases§ | 55 (38) | 30 (34) | 85 (37) | 56 (38) | 51 (39) | 107 (38) |
Charlson index | 2 (1–3) | 1 (1–2) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–3) |
Inhaled corticosteroids (alone or in combination) | 81 (57) | 47 (55) | 128 (56) | 82 (57) | 68 (53) | 150 (55) |
Long-acting bronchodilators (LAMA or LABA, alone or in combination) | 113 (80) | 73 (86) | 186 (82) | 116 (80) | 109 (85) | 225 (82) |
Pulmonary rehabilitation at baseline | 6 (4) | 5 (6) | 11 (5) | 6 (4) | 6 (5) | 12 (4) |
Pulmonary rehabilitation during follow-up | 6 (4) | 3 (3) | 9 (4) | 6 (4) | 6 (5) | 12 (4) |
Data are presented as n, mean±sd, n (%) or median (interquartile range). ITT: intention-to-treat; mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; LAMA: long-acting muscarinic antagonist; LABA: long-acting β-agonist. #: some variables have missing values, as follows. Per-protocol analysis set: socioeconomic status (n=1) active worker (n=10), GOLD 2017 assessment (n=2), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); ITT analysis set: socioeconomic status (n=2), active worker (n=11), GOLD 2017 assessment (n=3), cardiovascular disease, diabetes and musculoskeletal disease (n=1), Charlson index (n=1) and inhaled corticosteroids and long-acting bronchodilators (n=6); ¶: UK National Statistics Socio-economic Classification III, IV or V; +: chronic obstructive pulmonary disease severity mild (FEV1 ≥80% pred), moderate (FEV1 50–79% pred), severe FEV1 (30–49% pred), very severe (FEV1 <30% pred) and A (low risk, low symptom burden), B (low risk, high symptom burden), C (high risk, low symptom burden), D (high risk, high symptom burden); §: cardiovascular disease (International Classification of Diseases, 10th revision (ICD-10) I00–I99), diabetes mellitus (ICD-10 E10–E14), musculoskeletal diseases (ICD-10 M00–M99).